- 1 Supporting materials for
- 2 Morphological Insights in Oxidative Sensitive Nanocarriers Pharmacokinetics,
- 3 Targeting, and Photodynamic Therapy
- 4 Haitao Ding,^{a, † □} Liping Su,^{a, † □} Zhendong Xie,^{a,b,c, † □} Aroa Duro Castano,^d Yunkun
- 5 Li,^a Lorena Ruiz Perez,^{a,b,e} Junyang Chen,^{a,b,d} Kui Luo,^{a,f*} Xiaohe Tian,^{a*} Giuseppe
- 6 Battaglia,^{a,b,c,d,g*}

^aDepartment of Radiology and National Clinical Research Center for Geriatrics, Huaxi MR Research
Center (HMRRC), Frontiers Science Center for Disease-Related Molecular Network, State Key
Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu 610000, Sichuan
Province, China. ^bInstitute for Bioengineering of Catalunya (IBEC), The Barcelona Institute of Science
and Technology (BIST), Barcelona (Spain), Carrer Baldiri I Reixac, 08028, Barcelona, Spain.
^cDepartment of Electronic and Biomedical Engineering, University of Barcelona., Martí i Franquès 1,
08028, Barcelona, Spain ^dDepartment of Chemistry, University of Barcelona, Martí i Franquès 1,
08028, Barcelona, Spain. ^fFunctional and molecular imaging Key Laboratory of Sichuan Province, and
Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, Chengdu, 610041, China.
^gCatalan Institution for Research and Advanced Studies (ICREA), Passeig de Lluís Companys, 23,
08010, Barcelona, Spain.

- 19 **Corresponding authors.*
- 20 ⁺ ⁻*These authors contributed equally.*
- 21

22 Table of Contents

23	1. Main Experimental methods4
24	1.1. Stability4
25	1.2 Cell culture4
26	1.3 Cytotoxicity assessment4
27	1.4 Endocytosis pathways4
28	1.5 Sub-organelle colocalization experiment5
29 30	1.6 Physiological based pharmacokinetics (PBPK) model's parameter fitting and ranking
31	2. Supporting Figures
32 33	Fig. S1 (A-C) The average size of Ce6@PEG5k-PMET _{5/40/120} with time in water, PBS and 10% FBS
34	Fig. S2 Absorption spectra of PEG5k-PMET _{5/40/120} 6
35	Fig. S3 Fluorescence spectra of PEG5k-PMET _{5/40/120} 6
36	Fig. S4 In vitro cytotoxicity of PEG5k-PMET _{5/40/120} in QSG and HepG2 cells7
37	Fig. S5 In vitro cytotoxicity of Ce6@NPs in HepG2 cells without laser irradiation7
38 39 40	Fig. S6 (A) Fluorescence images of HepG2 cells stained with DCFH-DA and SOSG after treatment with Ce6@NPs for 24 hours. Quantification of the fluorescence intensity of DCFH-DA (B) and SOSG (C) in HepG2 cells treated with Ce6@NPs for 24 hours7
41 42 43	Fig.S7 Histogram results of Pearson coefficients of micelles, worms, and vesicles with Golgi (Golgi bodies), ER (endoplasmic reticulum), Lyso (lysosomes), and Mito (mitochondria) in HepG2 cells8
44 45	Fig.S8 The colocalization of micelle and organelles. Scale bar = 50 μm. (A) Golgi apparatus; (B) Endoplasmic reticulum; (C) Lysosomes; (D) Mitochondria
46 47	Fig.S9 The colocalization of worm and organelles. Scale bar = 50 μm. (A) Golgi apparatus; (B) Endoplasmic reticulum; (C) Lysosomes; (D) Mitochondria
48 49	Fig.S10 The colocalization of vesicle and organelles. Scale bar = 50 μm. (A) Golgi apparatus; (B) Endoplasmic reticulum; (C) Lysosomes; (D) Mitochondria9
50 51	Fig.S11 Flow cytometry detection of Effects of different endocytic inhibitors and temperature (4 °C) on the cellular uptake of micelle(A), worm(B), and vesicle(C)10
52 53	Fig.S12 <i>In vivo</i> fluorescent images of nude mice bearing HepG2 tumors treated with NPs@Ce6 (the concentration of Ce6 at 0.5 mg/mL) at different time-points10
54 55	Fig.S13 <i>Ex vivo</i> fluorescent images for harvested tumors and major organs at the 3 hours.
56	Fig.S14 <i>Ex vivo</i> fluorescent images for harvested tumors and major organs at the 6 hours.

57	
58	Fig.S15 <i>Ex vivo</i> fluorescent images for harvested tumors and major organs at the 24
59	hours12
60	Fig.S16 <i>Ex vivo</i> fluorescent images for harvested tumors and major organs at the 48
61	hours12
62	Fig. S17. Parameter rank based on global sensitivity in the PBPK model. The parameter
63	with the highest sensitivity in the model is ranked 10, while the one with the lowest
64	sensitivity is ranked 013
65	Fig.S18 H&E staining of the heart, liver, spleen, lung, and kidney after various
66	treatments13
67	3. Supporting Tables14
68	Table S1. Pharmacokinetic parameters for mice treated with NPs@Ce6 and free Ce6 by
69	fitting the data to a non-compartment model by PKSolver 2.0 software 14
70	

72 1. Main Experimental methods

73 **1.1. Stability**

To study the stability of Ce6@NPs, we incubated them in water, PBS and cell culture medium. Alteration of size and zeta potential were detected *via* DLS (Omni, Brookhaven Instrument, USA). Briefly, Ce6@NPs were incubated in above three conditions for 2 hours, 6 hours, 24 hours, 48 hours and 72 hours. At each time point, samples were measured *via* DLS.

78 **1.2 Cell culture**

HepG2 (human liver carcinoma cell line) and QSG (human hepatic cell line) were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). And they were cultured in the cell incubator under a humidified atmosphere at 37 °C (5% CO_2 , 95% air). The DMEM medium was used to culture QSG and HepG2 cells (containing 1% (v/v) penicillin-streptomycin, and 10% (v/v) fetal bovine serum). The cells out of the liquid nitrogen tank were passaged at least twice for experimental use.

84 **1.3 Cytotoxicity assessment**

HepG2 and QSG cells were seeded in 96-well plates and cultured in a normal oxygen incubator (5% CO₂, 37 °C). After 24 hours, PEG5k-PMET_{5/40/120} at an equivalent concentration of 0–200 μ g/mL was added in each well (n = 5 for each group). After 24 hours of incubation with contrast agents, the CCK-8 (Med Chem Express, USA) assay was performed to measure the cytotoxicity of experimental and control groups.

90 **1.4 Endocytosis pathways**

To clarify the endocytic pathway of NPs, HepG2 cells were seeded into 12-well plates. Next, cells and inhibitors (10 μ g/mL chlorpromazine, 10 μ M 2-deoxy-d-glucose, 10 μ M colchicine, and 50 mM NH₄Cl) were incubated for 30 minutes at 37 °C. After removing the above inhibitors, Ce6@NPs at a Ce6 concentration of 1 μ g/mL were added to the pre-incubated cells and incubated for an additional 3 hours. Another group of cells was pre-incubated for 30 minutes at 4 °C, followed by the addition of Ce6@NPs for an additional 3 hours. Cells cultured at room temperature without any treatment were used as controls. After completing the above treatment steps, the cells were collected, washed twice with PBS, and the fluorescence intensity inside the cells was detected by flow cytometry.

99 1.5 Sub-organelle colocalization experiment

100 HepG2 cells were inoculated on a glass substrate and incubated for 1 day. Micelle, worm and vesicle

101 were incubated with the cells. The concentration was determined based on the Ce6 (10 µg/mL) content.
102 After incubation for 3 hours, organelle staining reagents were added, including ER-Tracker Green
103 (Beyotime, C1042S), Lyso-Tracker Green (Beyotime, C1047S), Mito-Tracker Green (Beyotime, C1048),
104 and Golgi-Tracker Green (Beyotime, C1045S). After staining, the cells were washed twice, followed
105 by Hoechst 33342 staining (Yeasen, China) for 10 minutes, and then washed twice with PBS. Confocal
106 microscopy (CLSM, Nikon, Japan) was used to acquire images.

107 1.6 Physiological based pharmacokinetics (PBPK) model's parameter fitting and ranking

The PBPK model includes numerous parameters. To explore the parameter space and fit the parameter, we utilized particle swarm optimization (PSO) implemented via the Python package PySwarms, genetic algorithm (GA) via the Python package DEAP, and simulated annealing (SA) via the Python package SciPy. After we find out the parameter for different particle type, we analysised the parameter sensitivity. Sensitivity analysis can be divided into two categories: local sensitivity analysis and global sensitivity analysis¹. The sensitivity can be calculated as follows:

$$SC = \frac{(AUC_{0-\infty} - AUC_{0-\infty})/AUC_{0-\infty}}{(Par' - Par)/Par}.$$

where *SC* is the sensitivity; $^{AUC_0 - \infty}$ and $^{AUC_0 - \infty}$ is the area under curve before and under perturbed, respectively; and $^{Par'}$ and Par is the perturbed value and reference value of the parameter under investigation.

119 2. Supporting Figures



121 Fig. S1 (A-C) The average size of Ce6@PEG5k-PMET_{5/40/120} with time in water, PBS and 10% FBS.



122

123 Fig. S2 Absorption spectra of PEG5k-PMET_{5/40/120}.

124



125

126 Fig. S3 Fluorescence spectra of PEG5k-PMET_{5/40/120}.







131 Fig. S5 *In vitro* cytotoxicity of Ce6@NPs in HepG2 cells without laser irradiation.



Fig. S6 (A) Fluorescence images of HepG2 cells stained with DCFH-DA and SOSG after treatment with
Ce6@NPs for 24 hours. Quantification of the fluorescence intensity of DCFH-DA (B) and SOSG (C) in
HepG2 cells treated with Ce6@NPs for 24 hours.



138 Fig.S7 Histogram results of Pearson coefficients of micelles, worms, and vesicles with Golgi (Golgi

- 139 bodies), ER (endoplasmic reticulum), Lyso (lysosomes), and Mito (mitochondria) in HepG2 cells.
- 140



141

142 Fig.S8 The colocalization of micelle and organelles. Scale bar = 50 μ m. (A) Golgi apparatus; (B)

143 Endoplasmic reticulum; (C) Lysosomes; (D) Mitochondria.



146 Fig.S9 The colocalization of worm and organelles. Scale bar = 50 μ m. (A) Golgi apparatus; (B)

147 Endoplasmic reticulum; (C) Lysosomes; (D) Mitochondria.

148



150 Fig.S10 The colocalization of vesicle and organelles. Scale bar = 50 μ m. (A) Golgi apparatus; (B)

- 151 Endoplasmic reticulum; (C) Lysosomes; (D) Mitochondria.
- 152



153

154 Fig.S11 Flow cytometry detection of Effects of different endocytic inhibitors and temperature (4 °C)

- 155 on the cellular uptake of micelle(A), worm(B), and vesicle(C).
- 156



158 Fig.S12 In vivo fluorescent images of nude mice bearing HepG2 tumors treated with NPs@Ce6 (the

- 159 concentration of Ce6 at 0.5 mg/mL) at different time-points.
- 160



162 Fig.S13 *Ex vivo* fluorescent images for harvested tumors and major organs at the 3 hours.163



165 Fig.S14 *Ex vivo* fluorescent images for harvested tumors and major organs at the 6 hours.



Fig.S15 *Ex vivo* fluorescent images for harvested tumors and major organs at the 24 hours.

48 h



170

171 Fig.S16 *Ex vivo* fluorescent images for harvested tumors and major organs at the 48 hours.



174 Fig. S17. Parameter rank based on global sensitivity in the PBPK model. The parameter with the

175 highest sensitivity in the model is ranked 10, while the one with the lowest sensitivity is ranked 0.



177 Fig.S18 H&E staining of the heart, liver, spleen, lung, and kidney after various treatments.

3. Supporting Tables

179 Table S1. Pharmacokinetic parameters for mice treated with NPs@Ce6 and free Ce6 by fitting the

180	data to a non-compartment model by PKSolver 2.0 software.

Parameter	T _{1/2} (min)	$AUC_{0-\infty}$ (µg/mL·min)	CL (L/min/kg)	$MRT_{0-\infty}$ (min)
Micelle	313	794	0.126	378
Worm	563	898	0.111	518
Vesicle	428	729	0.137	459

183 1. P. Dogra, J. D. Butner, J. Ruiz Ramirez, Y. L. Chuang, A. Noureddine, C. Jeffrey Brinker, V.

184 Cristini and Z. Wang, *Comput Struct Biotechnol J*, 2020, **18**, 518-531.